18 results
Opioid Use Disorder Medications - Pharmacokinetics

Buprenorphine is a partial mu-opioid receptor agonist with low intrinsic activity,
receptor agonist ... margin of safety in pharmacology ... the sublingual tablet ... Pharmacokinetics #Comparison #Table ... #Pharmacology #
Pain Assessment and Management Initiative (PAMI) - Opioid Prescribing and Equianalgesic Chart - Agents and Dosing

#Management
Initiative (PAMI) - Opioid ... Dosing #Management ... #Pain #Pharmacology ... #Opioid #Opiate ... #Table #PAMI
Transdermal Fentanyl require unique dosing conversions. For Adult and pediatric patients taking opiouds or doses not
require unique dosing ... For Adult and pediatric ... Then using Table ... #Pharmacology #Pain ... #Opiate #Opioid
Pain Assessment and Management Initiative (PAMI) - Non-Opioid Analgesics - Agents and Dosing

#Management #Pain #Pharmacology #NonOpioid
Initiative (PAMI) - Non-Opioid ... Dosing #Management ... #Pain #Pharmacology ... Medications #Doses #Dosing ... #Table #PAMI
CA-Bridge Buprenorphine Hospital Quick Start Algorithm - Management of acute opiate withdrawal 
 - Any prescriber
Hospital Quick Start Algorithm ... high-affinity, partial agonist ... safe and highly ... If patient is stable ... Buprenorphine Dosing
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
GLP-1 Agonists ... Daily GLP-1 Agonists ... #GLP1 #Agonists ... #Pharmacology #Dosing ... Diabetes #DM2 #Endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
GLP-1 Receptor Agonists ... - Pharmacology ... Ozempic), or daily tablet ... #Pharmacology # ... DM2 #diabetes #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
Dosing: 3 mg ... oral route by using ... drug to remain stable ... semaglutide #Diabetes #Pharmacology ... #Endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... inactivates GLP-1 and ... GLP-I receptor agonist ... DPP4 #Inhibitors #Pharmacology ... DM2 #diabetes #endocrinology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
severe bleeding and ... #management #algorithm ... #pharmacology # ... #medications #table ... hematology #warfarin #dosing